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Background: Lung mucociliary clearance is impaired in patients with chronic obstructive
pulmonary disease (COPD). Treatment guidelines recommend that patients with COPD receive
maintenance therapy with long-acting beta-agonists and anticholinergic agents.
Methods: Twenty-four patients with mild to moderate COPD received formoterol (12 mg, twice
daily from Turbuhaler dry powder inhaler (DPI)) or tiotropium (18 mg, once daily from
Handihaler DPI) for 14 days. They also received single doses of formoterol, tiotropium, salbu-
tamol (200 mg) and placebo. A radioaerosol technique was used to assess the effects on mucus
clearance of 14 days treatment with formoterol or tiotropium, as well as single doses of these
drugs.
Results: The 4 h whole lung retention of radioaerosol was significantly higher after 14 days
treatment with tiotropium (P Z 0.016), but not after 14 days treatment with formoterol.
However, patients bronchodilated after 14 days treatment with both drugs, so that the depos-
ited radioaerosol may have had an increased distance to travel in order to be cleared by
mucociliary action. A single dose of formoterol enhanced radioaerosol clearance significantly
compared to other single dose treatments (P < 0.05).
Conclusion: Formoterol (12 mg) enhances mucus clearance in patients with mild to moderate
COPD when given as a single dose, and may do so when given for 14 days. Studies of longerctive pulmonary disease; FEV1, Forced expiratory volume in 1 s; FVC, Forced vital capacity; Kr,
hnetium.
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Treatment guidelines recommend that patients with
moderate or severe chronic obstructive pulmonary disease
(COPD) are given maintenance therapy with long-acting
inhaled bronchodilators.1 Both long-acting beta-agonists
(e.g. formoterol and salmeterol) and long-acting anticho-
linergic agents (e.g. tiotropium bromide) are effective in
the management of COPD,2 and can enhance quality of life.
Mucociliary clearance is a natural lung defence mecha-
nism,3 which helps to maintain a healthy environment in the
lungs. Mucociliary clearance is impaired in COPD patients,4
especially in the larger more central airways of the lungs.5
Patients may compensate for ineffective mucociliary clear-
ance of pulmonary secretions by increasing the amount of
mucus they clear by cough.6,7 Bronchodilating drugs may
influence mucus clearance,8,9 but the nature of the effects
depend on the type of drug and the length of time forwhich it
is administered. While tertiary ammonium compounds such
as atropine may slow mucociliary clearance,9,10 quaternary
ammonium compounds such as ipratropium bromide11 and
tiotropium bromide12 have been reported not do so. Beta-
agonists including fenoterol,13 salbutamol,14 and for-
moterol15 havebeen reported to enhancemucus clearance in
patients, or to increase ciliary beat frequency in animal
models.16
The effect of a bronchodilator on mucus clearance may
differ according to whether it is given continuously over
several weeks, or as a single dose. The objectives of this
study were to assess the effect on mucus clearance of (a)
treatment for 14 days with either formoterol or tiotropium,
and (b) single inhalations of formoterol or tiotropium. The
latter assessment used the short-acting beta-agonist
salbutamol as a comparator, and placebo as a control.
Formoterol and tiotropium were given by dry powder
inhalers (DPIs). Mucus clearance was assessed from the
retention of inhaled radioaerosol particles in the lungs.
Methods
Study population
Patients with an established clinical diagnosis of COPD,
having severities I (mild) or II (moderate) according to the
guidelines of the Global Initiative for COPD,1 were included
in the study. All patients had a cigarette smoking history,
which was defined by current or previous smoking of more
than 10 pack-years. An additional inclusion criterion was
the requirement for at least 4 weeks’ therapy on a stable
medication regimen before the screening visit. All patients
gave informed consent in writing, and the study was
approved by the local ethics committee and by the federal
office for radiation protection in Germany.
Unpublished data from patients with COPD who had
inhaled a radioaerosol in order to assess mucus clearancewere used to estimate the required number of subjects.
These data indicated a mean whole lung retention of
radiolabeled particles after 2 h of 82% (standard deviation
(SD) 8%). Considering a two-sided, two sample t-test,
a sample size of 18 subjects was required (alpha Z 5%,
power Z 80%). In order to obtain a balanced sample,
24 subjects were to be investigated.
Study design and treatment
The study was open-label, single-centre, randomised, and
cross-over in design. It was designed in order to allow the
effects of both 14 days therapy with either formoterol or
tiotropium, and single doses of the same drugs, to be
determined (Figs. 1 and 2). After the initial screening visit
(visit 1) and a 2e7 day run-in period, patients were
randomly assigned to receive for 14 days either formoterol
(metered dose 12 mg, Oxis, AstraZeneca) inhaled twice
daily via Turbuhaler DPI, or tiotropium (capsule dose
18 mg, Spiriva, Boehringer Ingelheim) inhaled once daily
via HandiHaler DPI. Each patient was given two devices,
such that patients receiving formoterol also inhaled from
a Handihaler containing empty capsules, while patients
receiving tiotropium also inhaled from an empty Tur-
buhaler. After a one week wash-out period, each patient
crossed over onto the other active treatment. Mucus
clearance was measured using a radioaerosol technique
before and after each two week treatment period (visits 2,
3, 4 and 5). The whole lung retention of the radioaerosol
after 2 h and 4 h was used as a measure of mucus clearance,
in order to assess the effects of the 14 day treatments.
The single dose study involved inhalation of either for-
moterol (12 mg, Oxis, AstraZeneca), tiotropium (18 mg,
Spiriva, Boehringer Ingelheim), salbutamol (200 mg,
Evohaler, GlaxoSmithKline) or placebo (empty Handihaler
capsules) at visits 2, 3, 4 and 5. Administration of the single
doses of drug or placebo took place 4 h after inhalation of
the radioaerosol, and was block-randomised across the four
visits using a Latin square design (Fig. 2). The whole lung
retentions of the radioaerosol after 4 h and 6 h were used as
measures of mucus clearance, in order to assess the effects
of single dose treatments.
Patients were trained in the correct use the Turbuhaler
for inhalation of formoterol, Handihaler for inhalation of
tiotropium, and pressurised metred dose inhaler (pMDI) for
inhalation of salbutamol, according to the manufacturer’s
instructions.
Permitted concomitant therapy during the study period
included short-acting theophylline, oral steroids, and sal-
butamol. Therapies with long-acting anticholinergic agents
(other than the study medication), long-acting beta-
agonists (other than the study medication), long-acting
theophylline, and inhaled corticosteroids were not
permitted for at least 48 h before visit 2, until completion
of visit 5. During each 6 h mucus clearance measurement,
Assessed for eligibility (n=24)
Randomized (n=24)
Allocated to 14 days treatment (n=24) Allocated to acute treatment (n=24)
Analysed  (n=24) Analysed  (n=24)
Figure 1 Description of study design, intended to assess the effects of 14 days treatment with formoterol or tiotropium, and
single doses of the same drugs.
902 T. Meyer et al.the use of any bronchodilators, apart from the single dose
intervention after 4 h, was not permitted. Smoking was
prohibited for the period beginning 2 h before radioaerosol
inhalation to 6 h afterwards. Inhalation of formoterol or
tiotropium was not permitted during the 12 h immediately
preceding visits 3 and 5.
Radioaerosol generation and inhalation
Radiolabeled iron oxide particles used for the clearance
measurements were produced by mixing iron (III)-oxide
colloid with stannous chloride solution and 99mTc-pertech-
netate.17 In a Sartorius dialysis cell, the chloride content of
this suspension was eliminated and aerosol particles were
produced with a spinning top aerosol generator. The aerosol
from the spinning top generator was led through a concen-
trator and the concentrated aerosol was passed through
a tube furnace at 800 C and mixed with reduction gas to
reduce iron (III)-oxide into iron (II, III)-oxide particles.Figure 2 Flow chaParticle size could be adjusted appropriately either by
changing the velocity of the spinning disk in the aerosol
generator or changing the concentration of iron (III)-oxide
colloid in the original suspension. The required mass
median aerodynamic diameter (MMAD) was 4.5 mm, and the
required geometric standard deviation (GSD) was 1.1.
The aerosol particles were produced immediately before
inhalation and were held in a reservoir from which the
patient inhaled. The specific radioactivity and particle size
in the reservoir was checked by withdrawing particles onto
a filter. If sufficient radioactivity was available, and if the
MMAD and GSD were within 10% of the required values,
subjects were allowed to inhale the particles. All inhala-
tions of test aerosol were controlled with a flow meter,
with a target inhaled flow rate of 15 L/min. The test aerosol
was given as an aerosol bolus which was inhaled
into a volumetric lung depth of 40% of dead space volume.
The quantity of 99mTc deposited in the lungs was
1.15  0.3 MBq.rt of the study.
Table 1 Demographics of 24 COPD patients completing
the study. There were 20 males and 4 females.
Mean SD Range
Age (y) 60.2 8.2 (40e76)
Height (m) 1.72 0.08 (1.56e1.88)
Weight (kg) 74.5 11.5 (46e94)
FEV1 (L) 2.06 0.56 (1.39e3.57)
FEV1 (% predicted) 67.2 12.8 (50e101)
FVC (L) 3.97 0.99 (2.45e6.23)
FVC (% predicted) 101.7 19.3 (66e139)
FEV1/FVC (%) 52.6 9.4 (35.2e68.5)
RV (L) 3.59 1.04 (1.88e5.20)
RV (% predicted) 154.5 36.4 (80e216)
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Clearance kinetics of the radiolabeled iron oxide particles
were assessed from the background and decay-corrected
decline in whole lung radioactivity during 6 h using a single-
headed gamma camera (Diacam, Siemens) with a 40 cm
field of view and a low energy parallel-hole collimator.
The duration of imaging was 5 min immediately after radi-
oaerosol inhalation, 6min at 2 h, 7min at 4 h and 8min at 6 h.
Patients were seated for imaging. In order to assess the lung
outlines and hence to define whole lung regions of interest,
a 81mKr gas ventilation scan was performed for each patient.
Percentage whole lung retention of radioaerosol during
visits 2, 3, 4 and 5 was quantified at 2 h, 4 h, and 6 h post
inhalation (Fig. 3). The lung image taken immediately after
radioaerosol inhalation was used as the 100% value. The
effects of 14 days treatment with formoterol or tiotropium
were assessed by comparing 2 h and 4 h retentions before and
after treatment. The effects of single doses of formoterol,
tiotropium, salbutamol or placebo were assessed from the
change in retention between 4h and 6h after each treatment.
During visit 2, the clearance measurement was extended
in order to measure 24 h retention of the iron oxide particles
(Fig. 2). The 24 h retention was determined from a compar-
ison of the background and decay-corrected counts obtained
immediately after inhalation and then 24 h later using
a purpose-built human lung counter.18 This 24 h retention in
the lungs was used as an indication of the proportion of
particles deposited in the non-ciliated airways and therefore
not available for mucociliary clearance.19
Forced expiratory volume in 1 s (FEV1), forced vital
capacity (FVC) and residual volume (RV) were measured by
body plethysmograph (MasterScreen Body, Jaeger).
Statistical differences in whole lung retention and in lung
function parameters were assessed from paired t-tests
using an Excel spreadsheet.
Results
Demographics of study population
Twenty-four patients (20 male, 4 female) with COPD
completed the study (Fig. 1, Table 1). The mean (SD) ageFigure 3 Schematic of mucus clearance measurements.
Percentage whole lung retention of radioaerosol was measured
at 2 h, 4 h and 6 h at each of visits 2, 3, 4 and 5. At visit 2, the
24 h whole lung retention was also measured.was 60.2 (8.2) y. FEV1 was 67.2 (12.8)% predicted, and FEV1
expressed relative to forced vital capacity (FVC) was 52.6
(9.4)%. RV was 154.5 (36.4)% predicted.
14 days treatment with formoterol
As shown in Fig. 4a, there were no significant differences in
radioaerosol retention in the whole lung at either 2 h
(before treatment 91.9 (7.7)%, after treatment 91.1
(9.8)%), or 4 h (before treatment 85.2 (9.9)%, after treat-
ment 84.8 (12.3)%). After treatment, patients had bron-
chodilated significantly, with FEV1 increasing from 1.82
(0.56) L before treatment to 2.10 (0.56) L afterwards
(P < 0.001, Table 2).
14 days treatment with tiotropium
As shown in Fig. 4b, whole lung retention measured 2 h
after radioaerosol inhalation was similar before and after
14 days treatment with tiotropium (92.3 (7.7)% versus 93.7
(8.5)%). However, whole lung retention at 4 h was signifi-
cantly lower before the 14 day treatment period compared
to after (85.9 (11.2)% versus 89.3 (12.4)%, PZ 0.016). After
treatment, patients had bronchodilated significantly, with
FEV1 increasing from 1.92 (0.62) L before treatment to 2.12
(0.60) L afterwards (P < 0.001, Table 2).
Single dose treatments
As shown in Fig. 5, whole lung retentions of radioaerosol
after 4 h in patients randomised to receive single doses ofTable 2 Mean (SD) lung function data before and after 14
days treatment with either formoterol or tiotropium.
Before After P
Formoterol
FEV1 (L) 1.82 (0.56) 2.10 (0.56) <0.001
FVC (L) 3.75 (0.95) 4.02 (0.92) 0.004
Tiotropium
FEV1 (L) 1.92 (0.62) 2.12 (0.60) <0.001
FVC (L) 3.80 (0.97) 4.01 (1.05) 0.023
Figure 4 Mean (þSD) whole lung radioaerosol retentions at 2 h and 4 h, before and after 14 day treatment periods with (a)
formoterol or (b) tiotropium. ) denotes a statistically significant difference compared with retention before treatment.
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similar. Whole lung retention at 6 h was lowest after for-
moterol (73.3 (13.4)%), and the difference was statistically
significant compared with placebo (81.2 (10.5)%, PZ 003).
Retentions measured 6 h after single doses of tiotropium
(77.6 (14.8)%), salbutamol (78.0 (14.1)%) and placebo were
not significantly different. The change in whole lung
retention between 4 and 6 h was highest for formoterol
(13.6 (7.4)%), and this change was significantly greater than
those for tiotropium (8.0 (7.4)%, P Z 0.021), salbutamol
(6.9 (6.5)%, PZ 0.005), or placebo (6.4 (5.2)%, PZ 0.002).
Lung function was similar prior to administration of each of
the four single dose treatments (Table 3).
24 h retention
Mean (SD) radioaerosol retention at 24 h, measured on one
study day, was 51.0 (8.8)%, suggesting that approximatelyFigure 5 Mean whole lung radioaerosol retentions at 2 h, 4 h
and 6 h, for study days on which single doses of formoterol,
tiotropium, salbutamol or placebo were administered after 4 h.half the radioaerosol was deposited on the ciliated airways
of the lungs, and approximately half on the non-ciliated
airways. Mean (SD) 24 h retention was 47.1 (7.8)% and 53.9
(9.3)%, respectively, in patients who received formoterol or
tiotropium at visit 2.
Discussion
Clearance of mucus from the human lung is usually
measured by radioaerosol methods,4,6,20,21 in which
pulmonary retention of radioaerosol is monitored by
gamma camera. This study has shown statistically signifi-
cant effects of the study medications on pulmonary mucus
clearance in patients with mild to moderate COPD.
Mucus clearance data between 4 h and 6 h after radio-
aerosol inhalation were used to assess the effects of single
doses of formoterol, tiotropium, salbutamol and placebo
administered after 4 h. The study was balanced in such
a way that the lung function parameters (FEV1 and FVC)
were not significantly different before administration of
each single dose. The data showed that a single dose of
formoterol (12 mg) enhanced mucus clearance in patients
with mild to moderate COPD, while a single dose of tio-
tropium (18 mg) had no effect. Positive effects of single
doses of inhaled beta-agonists have been shown in other
studies. Administration of single inhaled doses of feno-
terol13 and salbutamol14 have been shown previously toTable 3 Mean (SD) lung function before administration of
single doses of tiotropium, formoterol, salbutamol and
placebo.
Formoterol Tiotropium Salbutamol Placebo
FEV1 (L) 2.00 (0.58) 1.99 (0.70) 2.01 (0.58) 2.05 (0.55)
FVC (L) 3.98 (1.00) 3.83 (1.02) 3.94 (1.02) 4.08 (1.01)
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a single dose of 500 mg salbutamol was shown in another
study to enhance mucociliary clearance during the next
hour,14 no effect of a single dose of 200 mg salbutamol was
observed in this study.
The mucus clearance data up to 4 h after radioaerosol
inhalation were used to assess the effects of 14 days
treatment with either formoterol or tiotropium using
a cross-over study design. After 14 days treatment with
formoterol, lung retention of radioaerosol was unchanged
compared with that before treatment. Previous studies
have shown that terbutaline sulphate given for one week
either as tablets22 or as an aerosol23 did not increase
mucociliary clearance in COPD patients. However, in
another study, inhaled salbutamol (5 mg three times daily)
or a novel inhaled dopamine receptor/adrenoceptor
agonist increased mucociliary clearance when given to
COPD patients for 10 days.24
When mucus clearance was measured after 14 days
treatment with tiotropium, there was a significantly higher
retention in the lung after 4 h compared with the
measurement before treatment began. This observation
suggests a retardation of mucus clearance after 14 days
treatment with tiotropium. This finding differs from those
of an earlier study12 which concluded that 21 days treat-
ment with tiotropium (18 mg daily) did not adversely affect
mucus transport.
Salbutamol was allowed as rescue medication, in order
to maintain patient stability and well-being. Although sal-
butamol can affect mucus clearance in patients with
COPD,14 we think it unlikely that salbutamol use affected
the findings of this study. Of the 24 patients, only 3, 6, 7
and 3 patients took any salbutamol during the 6 h period
preceding each of visits 2, 3, 4 and 5. This may reflect the
fact that the patients had COPD rather than asthma. Sal-
butamol would not have influenced the effects of single
doses of either formoterol or tiotropium on mucus clear-
ance, assessed from the change in radioaerosol retention
between 4 h and 6 h, because no salbutamol was permitted
during each of the visits 2 to 5.
In this study, approximately 50% of the radioaerosol
particles were deposited on the conducting airways and 50%
in the alveoli, as based on the use of the 24 h retention of
particles as a measure of alveolar deposition. The frac-
tionation between conducting airways and alveoli was
similar for patients subsequently receiving formoterol or
tiotropium for 14 days. In theory, it is possible that radio-
aerosol could have been deposited at a site in the lungs
where one or both of the drugs was ineffective in terms of
its influence on mucus clearance. However, this seems
unlikely because the radioaerosol was distributed fairly
uniformly in the lungs, being divided approximately equally
between conducting airways and alveoli.
The rate of clearance of inhaled radioaerosol particles
depends on their initial deposition site in the lungs.25 If
particles are deposited peripherally, then the transit path
they must follow in order to undergo mucociliary clearance
is longer compared to that after central deposition. A
longer transit path could lead to an apparent reduction of
mucus clearance. The aerosol bolus delivery system used in
this study was designed to deliver the radioaerosol to
a reproducible deposition site in each individual.26However, after treatment for 14 days with both for-
moterol and tiotropium, the COPD patients had broncho-
dilated, and this may have led to more peripheral
radioaerosol deposition. Therefore, while 4 h retention
after 14 days treatment with formoterol was identical to
that before, this could be consistent with an enhancement
of mucus clearance. Similarly, while 4 h retention after 14
days treatment with tiotropium was increased compared
with that before treatment, this could be consistent with
mucus clearance being unchanged.
Mucus clearance occurs by both mucociliary and cough
clearance mechanisms,6 and the clearances observed in
this study may have resulted from a combination of both
processes. Mucociliary clearance depends on both ciliary
activity and the physical properties of mucus. Therefore,
while the data from this study indicate that a single dose of
inhaled formoterol may influence mucus clearance in
patients with mild to moderate COPD, it is not possible to
be specific about the mechanisms by which this effect took
place. However, beta-agonists are believed to enhance
mucociliary function in COPD patients,6,24,27,28 suggesting
that an enhancement of mucociliary function was respon-
sible for the effects of a single dose of formoterol seen in
this study.
It is important that the data from this study are not over-
interpreted. Although statistically significant effects of
long-acting bronchodilators on lung mucus clearance were
observed in this study, the clinical significance of these
findings is unclear. The changes observed in mucus clear-
ance, although statistically significant, were small in
magnitude. Studies of longer duration would be needed in
order to assess the effects of the study drugs on mucus
clearance when they are used for long-term maintenance
therapy.Financial support
This study was sponsored by AstraZeneca. AstraZeneca has
not influenced the study design, the collection, analysis and
interpretation of data; the writing of the manuscript; and
the decision to submit the manuscript for publication.Conflict of interest
All authors are disclosing any financial and personal rela-
tionships with other people or organisations that could
inappropriately influence (bias) their work on this
manuscript.References
1. GOLD Guidelines. Global initiative for chronic obstructive lung
disease, www.goldcopd.com; 2007.
2. Cooper CB, Tashkin DP. Recent developments in inhaled therapy
in stable chronic obstructive pulmonary disease. Br Med J 2005;
330:640e4.
3. Knowles MR, Boucher RC. Mucus clearance as a primary innate
defense mechanism for mammalian airways. J Clin Invest 2002;
109:571e7.
906 T. Meyer et al.4. Pavia D, Sutton PP, Agnew JE, Lopez-Vidriero MT, Newman SP,
Clarke SW. Measurement of bronchial mucociliary clearance.
Eur J Respir Dis 1983;64(Suppl. 127):41e56.
5. Smaldone GC, Foster WM, Riordan TGO, Messina MS, Perry RJ,
Langenback EG. Regional impairment ofmucociliary clearance in
chronic obstructive pulmonary disease.Chest 1993;103:1390e6.
6. Bennett WD, Almond MA, Zeman KL, Johnson JG, Donohoe JF.
Effect of salmeterol on mucociliary clearance and cough
clearance in chronic bronchitis. Pulm Pharmacol Ther 2005;19:
96e100.
7. Bennett WD, Chapman WF, Mascarella JM. The acute effect of
ipratropium bromide bronchodilator therapy on cough clear-
ance in COPD. Chest 1993;103:488e95.
8. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M.
Effectsofdrugsonmucusclearance.EurRespir J1999;14:452e67.
9. Foster WM, Bergofsky EH. Airway mucus membrane: effects of
beta-adrenergic and anticholinergic stimulation. Am J Med
1986;81:28e35.
10. Wanner A. Effect of ipratropium bromide on airway mucocili-
ary function. Am J Med 1986;14:23e7.
11. Taylor RG, Pavia D, Agnew JE, Lopez-Vidriero MT, Newman SP,
Lennard-Jones T, Clarke SW. Effect of four weeks’ high dose
ipratropium bromide treatment on lung mucociliary clearance.
Thorax 1986;41:295e300.
12. Hasani A, Toms N, Agnew JE, Sarno M, Harrison AJ, Dilworth P.
The effect of inhaled tiotropium bromide on lung mucociliary
clearance in patients with COPD. Chest 2004;125:1726e34.
13. Weich DJ, Viljoen H, Sweetlove MA, Pretorius PH, van
Rensburg AJ, Lo¨tter MG, Minnaar PC, Otto AC. Investigation into
the effect of fenoterol onmucociliary clearance in patientswith
chronic bronchitis. Eur J Nucl Med 1988;14:533e7.
14. Fazio F, Lafortuna C. Effect of inhaled salbutamol on muco-
ciliary clearance in patients with chronic bronchitis. Chest
1981;80(Suppl.):827e30.
15. Melloni B, Germouty J. The influence of a new beta agonist:
formoterol on mucociliary function. Rev Mal Respir 1992;9:
503e7.
16. Lindberg S, Khan R, Runer T. The effects of formoterol, a long-
acting beta 2-adrenoceptor agonist, on mucociliary activity.
Eur J Pharmacol 1995;285:275e80.17. Mo¨ller W, Scheuch G, Sommerer K, Heyder J. Preparation of
spherical monodisperse ferrimagnetic iron-oxide microparti-
cles between 1 and 5 mm. J Magnet Magn Mat 2001;225:
8e16.
18. Scheuch G, Stahlhofen W, Heyder J. An approach to deposition
and clearance measurements in the human airways. J Aerosol
Med 1996;9:35e41.
19. Brand P, Meyer T, Sommerer K, Weber N, Scheuch G. Alveolar
deposition of monodisperse aerosol particles in the lung of
patients with COPD. Exp Lung Res 2002;28:39e54.
20. Daviskas E, Anderson SD, Gonda I, Eberl S, Meikle S, Seale JP,
Bautovich G. Inhalation of hypertonic saline aerosol enhances
mucociliary clearance in asthmatic and healthy subjects. Eur
Respir J 1996;9:725e32.
21. Laube BL, Auci RM, Shields DE, Christiansen DH, Lucas MK,
Fuchs HJ, Rosenstein BJ. Effect of rhDNase on airflow
obstruction and mucociliary clearance in cystic fibrosis. Am J
Respir Crit Care Med 1996;153:752e60.
22. Sadoul P, Puchelle E, Zahm JM, Jacquot J, Aug F, Polu J-M.
Effect of terbutaline on mucociliary transport and sputum
properties in chronic bronchitis. Chest 1981;80(Suppl.):
885e9.
23. Pavia D, Bateman JRM, Sheahan NF, Clarke SW. Clearance of
lung secretions in patients with chronic bronchitis: effect of
terbutaline and ipratropium bromide aerosols. Eur J Respir Dis
1980;61:245e54.
24. Hasani A, Toms N, Agnew JE, Lloyds J, Dilworth JP. Muco-
ciliary clearance in COPD can be increased by both
a D2/beta2 and a standard beta2 agonist. Respir Med 2005;
99:145e51.
25. Pavia D, Bateman JRM, Sheahan NF, Agnew JE, Newman SP,
Clarke SW. Techniques for measuring lung mucociliary clear-
ance. Eur J Respir Dis 1980;61(Suppl. 110):157e77.
26. Scheuch G, Stahlhofen W. Deposition and dispersion of aerosols
in the airways of the human respiratory tract: the effect of
particle size. Exp Lung Res 1992;18:343e58.
27. Bennett WD. Effect of beta-adrenergic agonists on mucociliary
clearance. J Allergy Clin Immunol 2002;110:S291e7.
28. Johnson M, Rennard S. Alternative mechanisms for long-acting
beta-2 adrenergic agonists in COPD. Chest 2001;120:258e70.
